Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases

Contact Dermatitis
U JappeK Krohn

Abstract

Hypersensitivity to unfractionated and low-molecular-weight heparins and semisynthetic heparinoids is increasingly common. 7 female patients between 30 and 74 years with delayed-type allergy to heparins and semisynthetic heparinoids were investigated for (cross)-reactivity to fondaparinux, a new pentasaccharide with selective factor Xa inhibition. All patients showed delayed-type reactions to heparins and some additional cross-reaction to a heparinoid on intracutaneous testing. 6/7 tolerated fondaparinux on intradermal testing as well as on subcutaneous challenge testing. However, the 7th patient developed a characteristic delayed-type reaction to both skin tests with fondaparinux. Fondaparinux is a new synthetic pentasaccharide with a molecular weight of 1.728 Da. In some patients with cross-reactivity between various heparins and semisynthetic heparinoids, lepirudin, a recombinant hirudin, may be a safe and effective alternative. However, combined allergy to hirudin and heparins has been reported. Sometimes, intravenous administration of heparins or heparinoids may be tolerated. However, these patients are at risk of developing a systemic reaction. The pathogenesis of heparin hypersensitivity is not fully understood. Heparins...Continue Reading

References

Aug 1, 1994·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·D Greiner, H Schöfer
Nov 1, 1996·The Journal of Allergy and Clinical Immunology·A J BircherH Howald
Jul 31, 1999·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·U Jappe, H Gollnick
Jan 12, 2000·Gynecologic and Obstetric Investigation·G HuhleJ Harenberg
Sep 10, 2002·Journal of Computer Assisted Tomography·Stacey A FuntDavid M Panicek
Jul 19, 2003·Contact Dermatitis·P N WooA D Ormerod
Dec 18, 2003·Contact Dermatitis·Ralf J LudwigWolf-Henning Boehncke
Jul 28, 2004·Contact Dermatitis·Katrin HirschWolf-Henning Boehncke
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·N Lubenow, A Greinacher

❮ Previous
Next ❯

Citations

Apr 25, 2008·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·I Leonard BernsteinUNKNOWN American College of Allergy, Asthma and Immunology
Jan 24, 2006·Contact Dermatitis·J M L WhiteM Clement
Sep 30, 2009·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Marc SchindewolfRalf J Ludwig
Jan 28, 2014·Annales de dermatologie et de vénéréologie·C PhanA Soria
Sep 1, 2005·Current Opinion in Allergy and Clinical Immunology·Wolfgang UterAxel Schnuch
Feb 16, 2006·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Ajith WijesiriwardanaChristopher Lush
Nov 15, 2006·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Uta Jappe
Sep 17, 2010·Mayo Clinic Proceedings·Marc SchindewolfRalf J Ludwig
Jul 1, 2009·Immunology and Allergy Clinics of North America·Annick Barbaud
Jul 6, 2007·Journal of the American Academy of Dermatology·Peter KomerickiWerner Aberer
Dec 17, 2008·Contact Dermatitis·Luis Palacios ColomJoaquín Quiralte Enríquez
Jan 6, 2009·The British Journal of Dermatology·J WatonA Barbaud
Sep 5, 2006·La Revue de médecine interne·S EmilieC Pecquet
Jun 1, 2013·Obstetric Medicine·Ai-Wei Tang, Ian Greer
Nov 20, 2018·Contact Dermatitis·Marta TramontanaLuca Stingeni
Jan 10, 2018·Internal Medicine Journal·Elina TanMichaela Lucas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.